| Print |  E-mail

triangle_head.gif Stimulants

 


Millions of children in North America are diagnosed with attention deficit/hyperactivity disorder and treated with pyschostimulants such as methylphenidate, dextroamphetamine, and methamphetamine. These drugs produce a continuum of central nervous system toxicity that begins with increased energy, hyperalertness, and overfocusing on rote activities. It progresses toward obsessive compulsive or perseverance activities, insomnia, agitation, hypomania, mania, and sometimes seizures. They also commonly result in apathy, social withdrawal, emotional depression, and docility. Psychostimulants also cause physical withdrawal, including rebounding and dependence. They inhibit growth, and produce various cerebral dysfunctions, some of which can become irreversible.

 

The "therapeutic" effects of stimulants are a direct expression of their toxicity. Animal and human research indicates that these drugs often suppress spontaneous and social behaviors while promoting obsessive compulsive behaviors. These adverse drug effects make the psychostimulants seemingly useful for controlling the behavior of children especially in highly structured environments that do not attend to their genuine needs.

 

triangle_head.gif PDF Articles on pyschostimulants

 

triangle_head.gif Further articles on psychostimulants (HTML format)

 

 

 

 

Books by Dr. Breggin that address stimulant therapy

 

 

 

 

 

 

 

 

 

 

WARNING!

Most psychiatric drugs can cause withdrawal reactions, sometimes including life-threatening emotional and physical withdrawal problems. In short, it is not only dangerous to start taking psychiatric drugs, it can also be dangerous to stop them. Withdrawal from psychiatric drugs should be done carefully under experienced clinical supervision. Methods for safely withdrawing from psychiatric drugs are discussed in Dr. Breggin's new book, Psychiatric Drug Withdrawal: A Guide for Prescribers, Therapists, Patients, and Their Families.